Eupraxia Pharmaceuticals Inc
EPRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$287.26M
Close$
$1.44
83.2% downside
Current Fair Value
83.2% downsideOvervalued by 83.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $287.26 Million |
|---|---|
| Enterprise Value | $236.77 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.03 |
| Beta | 1.5 |
| Outstanding Shares | 66,221,815 |
Return
| Return on Equity | -45.08% |
|---|---|
| Return on Assets | -42.30% |
| Return on Invested Capital | -47.52% |
Valuation & Multiples
| P/E Ratio | -8.39 |
|---|---|
| PEG | -12.82 |
| Price to Sales | - |
| Price to Book Ratio | 8.58 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.8 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.23
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 37.47%▼ 1.73% |
|---|---|
| Total Invested | $163.63M▲ 3.39% |
| Investors Holding | 68▲ 13.00% |
ESG Score
No data